A short-term trial of tacrolimus ointment for atopic dermatitis

New England Journal of Medicine

Volumn 337, Issue 12, 1997, Pages 816-821

  Ruzicka, Thomas ^a   Bieber, Thomas ^b   Schöpf, Erwin ^c   Rubins, Andris ^d   Dobozy, Attila ^e   Bos, Jan D ^f   Jablonska, Stefania ^g   Ahmed, Imitiaz ^h   Thestrup Pedersen, Kristian ⁱ   Daniel, Francois ^j   Finzi, Aldo ^k   Reitamo, Sakari ^l  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

^d RIGA STRADINS UNIVERSITY   (Latvia)

^e UNIVERSITY OF SZEGED   (Hungary)

^f UNIVERSITY OF AMSTERDAM   (Netherlands)

^g Klinika Dermatologiczna Medical University of Warsaw   (Poland)

^h GEORGE ELIOT HOSPITAL   (United Kingdom)

ⁱ AARHUS UNIVERSITY HOSPITAL   (Denmark)

^j SAINT JOSEPH HOSPITAL   (France)

^k UNIVERSITY OF MILAN   (Italy)

^l HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; TACROLIMUS;

ADOLESCENT; ADULT; ARTICLE; ATOPIC DERMATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN DISEASE; SKIN MANIFESTATION; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; ADULT; DERMATITIS, ATOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; OINTMENTS; TACROLIMUS; TREATMENT OUTCOME;

EID: 0242322394     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199709183371203     Document Type: Article

References (21)

1. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 1980;92:44-7.
2. Merk H. Clinical symptoms of atopic eczema. In: Ruzicka T, Ring J, Przybilla B, eds. Handbook of atopic eczema. Berlin, Germany: Springer-Verlag, 1991:27-30.
3. Beltrani VS. The clinical manifestations of atopic dermatitis. In: Leung DYM, ed. Atopic dermatitis: from pathogenesis to treatment. Austin, Tex.: R.G. Landes, 1996:1-39.
4. Boguniewicz M, Leung DYM. Management of atopic dermatitis. In: Leung DYM, ed. Atopic dermatitis: from pathogenesis to treatment. Austin, Tex.: R.G. Landes, 1996:185-220.
5. De Rie MA, Meinardi MM, Bos JD. Lack of efficacy of topical cyclosporin A in atopic dermatitis and allergic contact dermatitis. Acta Derm Venereol 1991;71:452-4.
6. Thompson AW, Aldridge RD, Sewell HF. Topical cyclosporin in alopecia areata and nickel contact dermatitis. Lancet 1986;2:971-2.
7. de Prost Y, Bodemer C, Teillac D. Double-blind randomized placebo-controlled trial of local cyclosporine in atopic dermatitis. Acta Dermatol 1989;125:570.
8. Fung JJ, Todo S, Starzl TE. Tacrolimus in solid organ transplantation. In: Lieberman R, Mukherjee A, eds. Principles of drug development in transplantation and autoimmunity. Austin, Tex.: R.G. Landes, 1996:183-90.
9. Goto T, Kino T, Hatanaka H, et al. FK 506: historical perspectives. Transplant Proc 1991;23:2713-7.
10. Lauerma AI, Maibach HI, Granlund H, Erkko P, Kartamaa M, Stubb S. Inhibition of contact allergy reactions by topical FK506. Lancet 1992; 340:556.
11. Nakagawa H, Etoh T, Ishibashi Y, et al. Tacrolimus ointment for atopic dermatitis. Lancet 1994;344:883.
12. Idem. Effects of tacrolimus (FK506) ointment for facial atopic dermatitis. Allergy 1995;50:Suppl 26:368. abstract.
13. Kawashima M, Nakagawa H, Ohtsuki M, Tamaki K, Ishibashi Y. Tacrolimus concentrations in blood during topical treatment of atopic dermatitis. Lancet 1996;348:1240-1.
14. Rajka G, Langeland T. Grading of the severity of atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 1989;144:13-4.
15. Jonckheere AR. A distribution-free k-sample test against ordered alternatives. Biometrika 1954;41:133-45.
16. The European FK 506 Multicentre Psoriasis Study Group. Systemic tacrolimus (FK 506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study. Arch Dermatol 1996;132:419-23.
17. Kershner RP, Fitzsimmons WE. Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. Transplantation 1996;62:920-6.
18. Meingassner JG, Stütz A. Immunosuppressive macrolides of the type FK 506: a novel class of topical agents for treatment of skin diseases? J Invest Dermatol 1992;98:851-5.
19. Sowden JM, Berth-Jones J, Ross JS, et al. Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis. Lancet 1991;338:137-40.
20. van Joost T, Heule F, Korstanje M, van den Broek MJ, Stenveld HJ, van Vloten WA. Cyclosporin in atopic dermatitis: a multicentre placebo-controlled study. Br J Dermatol 1994;130:634-40.
21. Granlund H, Erkko P, Sinisalo M, Reitamo S. Cyclosporin in atopic dermatitis: time to relapse and effect of intermittent therapy. Br J Dermatol 1995;132:106-12.